Paroxysmal nocturnal hemoglobinuria without GPI-anchor deficiency.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
02 12 2019
Historique:
pubmed: 23 10 2019
medline: 21 5 2020
entrez: 23 10 2019
Statut: ppublish

Résumé

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired disorder characterized by hemolysis, thrombosis, and bone marrow failure caused by defective expression of glycosylphosphatidylinositol-anchored (GPI-anchored) complement inhibitors. Most commonly, PNH is caused by loss of function of PIGA, which is required for GPI biosynthesis. In this issue of the JCI, Höchsmann et al. report on 4 PNH patients who also had marked autoinflammatory manifestations, including aseptic meningitis. All 4 patients had a germline mutation of the related gene PIGT and a somatically acquired myeloid common deleted region (CDR) on chromosome 20q that deleted the second PIGT allele. The biochemistry and clinical manifestations indicate that these patients have subtle but important differences from those with PNH resulting from PIGA mutations, suggesting PIGT-PNH may be a distinct clinical entity.

Identifiants

pubmed: 31638602
pii: 131647
doi: 10.1172/JCI131647
pmc: PMC6877310
doi:
pii:

Substances chimiques

Glycosylphosphatidylinositols 0
Inflammasomes 0
Complement System Proteins 9007-36-7

Types de publication

Journal Article Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

5074-5076

Commentaires et corrections

Type : CommentOn

Références

Am J Clin Pathol. 1996 Nov;106(5):680-8
pubmed: 8929482
Blood. 2019 Feb 7;133(6):530-539
pubmed: 30510080
J Clin Invest. 2014 Oct;124(10):4529-38
pubmed: 25244093
J Lipid Res. 2016 Jan;57(1):6-24
pubmed: 26563290
N Engl J Med. 2006 Sep 21;355(12):1233-43
pubmed: 16990386
Cell. 1997 Jan 10;88(1):1-4
pubmed: 9019395
Cell. 1993 May 21;73(4):703-11
pubmed: 8500164
Eur J Haematol. 2014 Jun;92(6):467-70
pubmed: 24612308
Br J Haematol. 2004 Jul;126(1):133-8
pubmed: 15198744
Lancet. 1996 Aug 31;348(9027):573-7
pubmed: 8774569
Blood. 2013 Aug 15;122(7):1312-5
pubmed: 23733340
Nat Biotechnol. 2007 Nov;25(11):1256-64
pubmed: 17989688
Blood. 2008 Feb 15;111(4):1840-7
pubmed: 18055865
J Blood Med. 2016 May 30;7:107-10
pubmed: 27313483
Stem Cells Transl Med. 2013 Nov;2(11):819-29
pubmed: 24113066
Nat Rev Dis Primers. 2017 May 18;3:17028
pubmed: 28516949
J Clin Invest. 2019 Dec 2;129(12):5123-5136
pubmed: 31430258
Am J Clin Pathol. 2000 Sep;114(3):459-66
pubmed: 10989647
Blood. 2006 Dec 15;108(13):4232-6
pubmed: 16940417

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH